Organization
Institut Claudius Regaud, Institut Universitaire du Cancer – Oncopole, Toulouse, France
2 abstracts
Abstract
Influence of hormone therapy timing intake on disease free survival (DFS) for patients with high-risk early breast cancer: Results of the UCBG-UNIRAD phase III randomized trial.Org: APHP University Hopital Saint Louis, Senopole, Paris, France, Surgery Department, Institut Curie, Universite Paris Cite, Paris, France, Medical Oncology, Centre Léon Bérard, Lyon, France, R&D Unicancer, Paris, France, Institut Gustave Roussy, Villejuif, France, Edinburgh University Cancer Centre, Edinburgh, Scotland, United Kingdom, Medical Oncology,
Abstract
Capivasertib (C) and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2– advanced breast cancer (ABC): Characterization and management of common adverse events (AEs) from the phase 3 CAPItello-291 trial.Org: University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, Medical Oncology Department and Breast Cancer Group, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, The University of Manchester, Manchester, United Kingdom, The Christie NHS Foundation Trust, Manchester, United Kingdom, Institut Claudius Regaud, Institut Universitaire du Cancer – Oncopole, Toulouse, France,